Prapela

About:

Prapela is a noninvasive stimuation therapy that improves breathing and oxygenation in newborns.

Website: https://prapela.com/

Top Investors: U.S. Small Business Administration, National Institutes of Health, Massachusetts Life Sciences Center, National Institute on Drug Abuse (NIDA), Baylor College of Medicine

Description:

Prapela is an affordable, noninvasive stimulation therapy that improves newborn health. Our focus is on three clinical problems experienced by thousands of newborns every day. Placed inside a hospital bassinet or incubator, our reusable pad provides gentle stimulation that helps improve the natural processes of breathing control and oxygenation. Since receiving our first award in 2017, Prapela has become America's most-awarded pediatric medical device startup. With over $8M in grants (and hopefully more), we are honored and motivated to work with neonatologists, the National Institutes of Health, and the FDA to improve the health of newborns.

Total Funding Amount:

$8.23M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Biddeford, Maine, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)prapela.com

Founders:

David Morrill, David Paydarfar, MD, Jim Niemi, John Konsin

Number of Employees:

1-10

Last Funding Date:

2023-12-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai